Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation · 2026
Outcomes of Combined Hepatocellular-Cholangiocarcinoma After Surgical and Nonsurgical Treatments: A 23-Year Study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
De Godos Andrea González, Cuadrado Martín Bailón, Fuentes Pilar Pinto, Rodríguez Vielba Paloma Lourdes, Díaz Enrique Asensio, Rodríguez Fernando Labarga, Tejero Pintor Francisco Javier, Sánchez David Pacheco
Аннотация
OBJECTIVES: Combined hepatocellular -cholangiocarcinoma is a rare primary liver cancer with an incidence that ranges from 0.4 % to 14.2 % among primary liver cancers, characterized by mixed clinicopathological features of hepatocellular carcinoma and cholangiocarcinoma. Here, we evaluated the incidence, diagnostic challenges, treatment modalities, and long -term outcomes of combined hepatocellular -cholangiocarcinoma at a single tertiary center.
MATERIALS AND METHODS: This retrospective observational study, conducted from January 2000 through May 2023, included patients diagnosed with combined hepatocellular -cholangiocarcinoma per 2019 World Health Organization criteria. We analyzed data on overall survival, disease -free survival, recurrence, and treatment by using Kaplan -Meier and log -rank tests.
RESULTS: Of 21 initially identified patients, 13 met inclusion criteria of having combined hepatocellular -cholangiocarcinoma: 7 (53.8 % ) underwent liver transplant and were diagnosed incidentally, 2 under -went resection, 2 received systemic chemotherapy, and 2 received palliative care. Mean overall survival was 56.31 months (95 % CI, 19.12-93.49 ), with significant differences between groups (P < .001 ), showing results of 58 months (resection ), 72.57 months (transplant ), 15.50 months (chemotherapy ), and 0 months (palliative care ). Local recurrence occurred in 2 patients (15.4 % ). Mean disease -free survival was 110.66 months (95 % CI, 57.02 -164.30 ).
CONCLUSIONS: This 23 -year study highlights the diagnostic and therapeutic challenges of combined hepatocellular -cholangiocarcinoma, with a median overall survival of 18 months and frequent incidental diagnosis posttransplant. Multicenter studies are needed to standardize management and improve outcomes.
MATERIALS AND METHODS: This retrospective observational study, conducted from January 2000 through May 2023, included patients diagnosed with combined hepatocellular -cholangiocarcinoma per 2019 World Health Organization criteria. We analyzed data on overall survival, disease -free survival, recurrence, and treatment by using Kaplan -Meier and log -rank tests.
RESULTS: Of 21 initially identified patients, 13 met inclusion criteria of having combined hepatocellular -cholangiocarcinoma: 7 (53.8 % ) underwent liver transplant and were diagnosed incidentally, 2 under -went resection, 2 received systemic chemotherapy, and 2 received palliative care. Mean overall survival was 56.31 months (95 % CI, 19.12-93.49 ), with significant differences between groups (P < .001 ), showing results of 58 months (resection ), 72.57 months (transplant ), 15.50 months (chemotherapy ), and 0 months (palliative care ). Local recurrence occurred in 2 patients (15.4 % ). Mean disease -free survival was 110.66 months (95 % CI, 57.02 -164.30 ).
CONCLUSIONS: This 23 -year study highlights the diagnostic and therapeutic challenges of combined hepatocellular -cholangiocarcinoma, with a median overall survival of 18 months and frequent incidental diagnosis posttransplant. Multicenter studies are needed to standardize management and improve outcomes.